SARMs and research peptides are often mentioned together, but they are studied for different purposes and act through entirely different biological pathways. This guide breaks down the practical and mechanistic differences so you can navigate the catalogue with confidence. Everything below is provided for laboratory and educational research purposes only.
What are SARMs?
Selective androgen receptor modulators (SARMs) are non-steroidal compounds designed to bind the androgen receptor. In published pharmacology, ligand binding induces conformational changes in the receptor's ligand-binding domain that can favour tissue-selective gene regulation, with the research aim of anabolic activity in muscle and bone and reduced activity in other androgen-sensitive tissues. In preclinical and early clinical research they have been investigated around lean mass, strength and body recomposition. Explore them in our Bioreactive Series.
What are research peptides?
Peptides are short chains of amino acids linked by peptide bonds. In the scientific literature they are studied as highly specific signalling molecules that interact with cell-surface receptors and enzymes, and the therapeutic-peptide field spans more than a hundred candidates across metabolic, recovery, growth-factor and tissue-repair pathways. In a research context, peptides are typically of interest for recovery, regeneration and signalling studies rather than direct androgen-receptor activity. Our oral Peptides range is needle-free and batch-tested.
How do their mechanisms differ?
The core distinction is the target. SARMs act intracellularly at the androgen receptor, behaving as a single receptor system that influences gene transcription. Peptides are far more diverse: each sequence is studied for its own receptor or enzyme interaction, so a peptide's research profile depends entirely on its amino-acid sequence. This means SARMs are studied as one comparatively uniform mechanism, whereas "peptides" is an umbrella term covering many distinct signalling pathways with no single shared mode of action.
What does the research show?
For SARMs, reviews describe early-stage investigation into muscle wasting, body composition and related endpoints, while also noting that head-to-head clinical superiority over conventional androgens has not been established and that findings remain preliminary. For peptides, the literature documents a large and growing class with several approved peptide medicines in other contexts, alongside many candidates still under study. In both cases the published evidence is the basis for laboratory research interest, not a claim of proven outcomes for any specific compound sold here.
How are they administered in research settings?
Administration format is a practical point of difference often discussed in the literature. Many SARMs are studied as orally bioavailable small molecules. Peptides are frequently fragile in the digestive tract, so historically they have been studied via injectable routes, though oral and other delivery formats are an active area of formulation research. The products referenced here are supplied as research materials and are not formulated, dosed or labelled for human use; no administration guidance for people is provided or implied.
SARMs vs peptides: side-by-side comparison
| Attribute | SARMs | Research peptides |
|---|---|---|
| Chemical class | Non-steroidal small molecules | Short amino-acid chains |
| Primary target | Androgen receptor | Sequence-specific receptors and enzymes |
| Mechanistic uniformity | Relatively uniform single-receptor mechanism | Diverse; varies per peptide |
| Common research focus | Lean mass, strength, recomposition | Recovery, signalling, tissue-repair pathways |
| Typical study format | Often orally bioavailable | Often injectable; oral formats under research |
| Regulatory status | Not an approved medicine | Class includes approved drugs, but research compounds here are not approved medicines |
Which category fits a given research goal?
For research framed around mass and strength endpoints, SARMs are the usual starting point because of their androgen-receptor focus. For research framed around recovery, regeneration or specific signalling questions, peptides are more relevant, with the exact choice depending on the sequence and pathway under study. Many research designs reference both classes; our AI Stack Advisor can suggest a goal-based combination instantly. None of this constitutes a recommendation for personal use.
Are SARMs and peptides approved medicines in the UK?
No. The SARMs and research peptides referenced here are research compounds and are not authorised medicines. They have not been evaluated or approved as medicines by the MHRA, EMA or FDA, and no medical, therapeutic or performance claims are made for them. They are intended strictly for in-vitro and laboratory research and are not for human or animal consumption.
Research references
- Solomon ZJ, Mirabal JR, Mazur DJ, Kohn TP, Lipshultz LI, Pastuszak AW. Selective Androgen Receptor Modulators: Current Knowledge and Clinical Applications. Sexual Medicine Reviews. 2019;7(1):84-94. DOI: 10.1016/j.sxmr.2018.09.006
- Bond P, Smit DL, Verdegaal T, de Ronde W. Selective androgen receptor modulators: a critical appraisal. Frontiers in Endocrinology. 2025. DOI: 10.3389/fendo.2025.1634799
- Wang L, Wang N, Zhang W, et al. Therapeutic peptides: current applications and future directions. Signal Transduction and Targeted Therapy. 2022;7:48. DOI: 10.1038/s41392-022-00904-4
Research-use disclaimer: This article is for laboratory and educational research purposes only. The compounds discussed are not approved medicines, are not evaluated by the MHRA, EMA or FDA, and are not for human consumption. No dosing or medical guidance is provided.